{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T14:52:04Z","timestamp":1774709524785,"version":"3.50.1"},"reference-count":29,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,1,23]]},"abstract":"<jats:p>Rituximab generally is a well-tolerated medication used in a variety of haematological and autoimmune conditions. The safety profile of the medication has been reviewed in the literature. Infusion reactions due to cytokine release are the most common side effects. With the increased use of rituximab, there is an increase incidence of cytopenias, most commonly thrombocytopenia and leucopenia. Coagulopathy is quite rare, reported previously in four cases in the literature. We highlighted the clinical course of a 39-year-old patient with precursor B-cell acute lymphoblastic leukaemia who was started on rituximab infusion. The patient developed a cytokine-release syndrome with haemodynamic instability, followed by rapid-onset cytopenias and disseminated intravascular coagulation abnormalities characterised by coagulopathy with fibrinolysis and mucocutaneous bleeding. The report is followed by a review of the literature. It is important to recognise rituximab-induced coagulopathy early as part of the differential diagnosis of thrombocytopenia and disseminated intravascular coagulation following rituximab administration.<\/jats:p>","DOI":"10.1136\/bcr-2016-218443","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T10:30:21Z","timestamp":1486549821000},"page":"bcr2016218443","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Disseminated intravascular coagulation-like reaction following rituximab infusion"],"prefix":"10.1136","volume":"2017","author":[{"given":"Hind","family":"Rafei","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, George Washington University School of Medicine & Health Sciences, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah","family":"Nassereddine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, George Washington University School of Medicine & Health Sciences, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan F","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,2,8]]},"reference":[{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.1","unstructured":"US Department of Health and Human Services 2010. Common terminology criteria for adverse events v4. 03."},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.2","unstructured":"Rituxan [package insert]. South San Francisco, CA: Genentech, Inc., 2011."},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab-a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Critical Care"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.5","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500473113"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.leu.2401987","article-title":"Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion","volume":"15","author":"Rigamonti","year":"2001","journal-title":"Leukemia"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.20028","article-title":"Case report of rituximab-induced thrombocytopenia","volume":"75","author":"Shah","year":"2004","journal-title":"Am J Hematol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.20218","article-title":"Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia","volume":"78","author":"Pamuk","year":"2005","journal-title":"Am J Hematol"},{"issue":"(Suppl)","key":"2025082802103512000_2017.feb08_1.bcr2016218443.9","first-page":"ECR23","article-title":"Rituximab-induced acute thrombocytopenia: a report of two cases","volume":"90","author":"Otrock","year":"2005","journal-title":"Haematologica"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2141.2006.06299.x","article-title":"Rituximab-induced haemorrhagic thrombocytopenia in a patient with hairy cell leukaemia","volume":"135","author":"Thachil","year":"2006","journal-title":"Br J Haematol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.11","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1080\/10428190701625099","article-title":"Severe acute thrombocytopenia following rituximab therapy","volume":"48","author":"Rosado","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12032-008-9079-6","article-title":"Rituximab-induced acute thrombocytopenia: a case report and review of the literature","volume":"26","author":"Yi","year":"2009","journal-title":"Med Oncol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/07357900802010509","article-title":"Rituximab-induced severe acute thrombocytopenia: a case report and review of literature","volume":"26","author":"Dhand","year":"2008","journal-title":"Cancer Invest"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21372"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ajh.21597","article-title":"Severe thrombocytopenia and fibrinolysis mimicking disseminated intravascular coagulation after rituximab infusion","volume":"85","author":"Kotsianidis","year":"2010","journal-title":"Am J Hematol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00277-009-0768-9","article-title":"Thrombocytopenia with rituximab treatment\u2014splenomegaly as the risk factor","volume":"89","author":"Adiyodi","year":"2010","journal-title":"Ann Hematol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2141.2010.08119.x","article-title":"Rituximab-induced acute severe thrombocytopenia","volume":"149","author":"Parajuli","year":"2010","journal-title":"Br J Haematol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.18","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3109\/10428194.2013.784972","article-title":"Rituximab-induced acute thrombocytopenia: an underappreciated entity","volume":"54","author":"El-Osta","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.clml.2013.04.013","article-title":"Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma","volume":"13","author":"Sadashiv","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01808.x"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.21","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3109\/10428194.2010.523127","article-title":"Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenstr\u00f6m macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination","volume":"51","author":"Pilorge","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.22","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3109\/10428194.2012.682313","article-title":"Rituximab-induced coagulopathy","volume":"53","author":"Novak","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.23059"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF02685907","article-title":"Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma","volume":"24","author":"Avil\u00e9s","year":"2007","journal-title":"Med Oncol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.25","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.E10-E21"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.26","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.27","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"key":"2025082802103512000_2017.feb08_1.bcr2016218443.29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04385.x"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-218443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:10:45Z","timestamp":1756372245000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-218443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,8]]},"references-count":29,"alternative-id":["10.1136\/bcr-2016-218443"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-218443","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,8]]}}}